<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266369</url>
  </required_header>
  <id_info>
    <org_study_id>AB06013</org_study_id>
    <nct_id>NCT01266369</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation</brief_title>
  <official_title>A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open-label, 2-parallel Group, Phase IIa Study to Compare Efficacy and Safety of AB1010 at 3 or 6 mg/kg/Day in Treatment of Patients With Mastocytosis With Handicap and Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of&#xD;
      patients with mastocytosis with handicap and bearing activating point mutations in the&#xD;
      phosphotransferase domain of c-Kit such as the main mutation Asp-816-Val (D816V).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy on handicaps</measure>
    <time_frame>week 12</time_frame>
    <description>Pruritus score at week 12 Number of flushes per week at week 12 Hamilton score at week 12 Fatigue Impact scale at week 12</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Mastocytosis</condition>
  <arm_group>
    <arm_group_label>masitinib 3 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib 3 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib 6 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib</intervention_name>
    <arm_group_label>masitinib 3 mg/kg/day</arm_group_label>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with one of the following documented mastocytosis:&#xD;
&#xD;
               -  Smouldering systemic mastocytosis&#xD;
&#xD;
               -  Indolent systemic mastocytosis with organomegaly&#xD;
&#xD;
               -  Indolent Systemic Mastocytosis having 2 infiltrated organs (skin and bone-marrow)&#xD;
&#xD;
               -  Any mastocytosis with in the last 6 months at least 3 anaphylactic shocks or&#xD;
                  syncops requiring either use of adrenaline or medical assistance&#xD;
&#xD;
               -  Cutaneous Mastocytosis (CM)&#xD;
&#xD;
          2. Skin biopsy-documented mastocytosis and evaluable disease based upon:&#xD;
&#xD;
               -  Histological criteria: typical infiltrates of mast cells in a multifocal or&#xD;
                  diffuse pattern in skin biopsy&#xD;
&#xD;
               -  Clinical criteria: typical skin lesions (maculopapular, urticaria pigmentosa,&#xD;
                  mastocytoma)&#xD;
&#xD;
          3. Missing data (c-kit molecular analysis not done) or documented presence of an&#xD;
             activating point mutation in the phosphotransferase domain of c-kit such as D816V&#xD;
             c-kit mutation in at least one infiltrated organ (bone marrow or skin)&#xD;
&#xD;
          4. Refractory to at least one of the symptomatic treatments such as:&#xD;
&#xD;
               -  Anti H1&#xD;
&#xD;
               -  Anti H2&#xD;
&#xD;
               -  Proton pump inhibitor&#xD;
&#xD;
               -  Osteoclast inhibitor&#xD;
&#xD;
               -  Cromoglycate Sodium&#xD;
&#xD;
               -  Antileukotriene&#xD;
&#xD;
               -  Other therapies used for the symptomatic care&#xD;
&#xD;
          5. Handicap defined as at least one of the following handicaps:&#xD;
&#xD;
               -  pruritus score ≥ 6&#xD;
&#xD;
               -  number of flushes per week ≥ 7&#xD;
&#xD;
               -  number of stools per day ≥ 4 ,&#xD;
&#xD;
               -  number of mictions per day ≥ 8 ,&#xD;
&#xD;
               -  QLQ-C30 score ≥ 60,&#xD;
&#xD;
               -  Hamilton score ≥ 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with one of the following mastocytosis:&#xD;
&#xD;
               -  Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage&#xD;
                  Disease (SM-AHNMD)&#xD;
&#xD;
               -  Mast cell leukemia (MCL)&#xD;
&#xD;
               -  Aggressive systemic mastocytosis (ASM)&#xD;
&#xD;
          2. Patient with a major surgery within 2 weeks prior to study entry&#xD;
&#xD;
          3. No vulnerable population will be included in this study&#xD;
&#xD;
               -  Life expectancy &lt; 6 months.&#xD;
&#xD;
               -  Patient is &lt; 5 years free of malignancy, except treated basal cell skin cancer or&#xD;
                  cervical carcinoma in situ.&#xD;
&#xD;
               -  Patient with grade III/IV cardiac problems as defined by the New York Heart&#xD;
                  Association Criteria. (i.e., congestive heart failure, myocardial infarction&#xD;
                  within 6 months of study)&#xD;
&#xD;
               -  Patient has a severe and/or uncontrolled medical disease.&#xD;
&#xD;
               -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lortholary, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital, Paris, France</affiliation>
  </overall_official>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastocytosis</keyword>
  <keyword>D816V</keyword>
  <keyword>handicaps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

